Results 141 to 150 of about 10,873 (203)

Defining the potential role of the mineralocorticoid receptor in musculoskeletal health and bone crosstalk with other tissues. [PDF]

J Endocrinol
Bensreti H, Shaver JC, Yearwood CL, Alhamad DW, Morey EC, Sultana S, Hamrick MW, Kosmac K, Bollag WB, Belin de Chantemele EJ, Isales CM, McGee-Lawrence ME.   +11 more
europepmc   +1 more source

Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis. [PDF]

BMC Ophthalmol
Park JY, Jang Y, Hahn S.
europepmc   +1 more source

Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024. [PDF]

Front Pharmacol
Ji K, Huang X, Wang F, Zhang L, Zheng Y, Ji L, Ju Y, Zhuang X, Li J.   +8 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease. [PDF]

Diabetes Obes Metab
Mottl AK, Khunti K, Mathieu C.
europepmc   +1 more source

Real-World Utilisation and Cost Trends of Mineralocorticoid Receptor Antagonists in England: A Population-Level Prescribing Analysis From 2022 to 2025. [PDF]

Cardiovasc Ther
Kow CS, Hasan SS, Thiruchelvam K, Zaihan AF.   +3 more
europepmc   +1 more source

Urinary nephrin as an early biomarker of podocyte dysfunction in essential hypertension: a stage-stratified study from Bukhara, Uzbekistan. [PDF]

Front Cardiovasc Med
Amonov MKO.
europepmc   +1 more source

Renal Function Stratified Dose Comparisons of Eplerenone Versus Placebo in the EMPHASIS-HF Trial [PDF]

European Journal of Heart Failure, 2019
BACKGROUND: Current heart failure guidelines recommend target eplerenone dose of 50 mg/day. We have examined the effect of different eplerenone doses based on pre-specified renal function stratification in the Eplerenone in Mild Patients Hospitalization ...
Bertram Pitt, Faiez Zannad, John Vincent
exaly   +2 more sources

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms

New England Journal of Medicine, 2011
BACKGROUND: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction.
Bertram Pitt, Faiez Zannad, John Vincent
exaly   +2 more sources

History of Hypertension and Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure

Hypertension, 2008
In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study ( n = 6632), eplerenone- associated reduction in all- cause mortality was significantly greater in those with a history of hypertension ( Hx- HTN).
Bertram Pitt, Faiez Zannad, Henry Krum
exaly   +2 more sources